Sipuleucel-T is the first drug for metastatic hormone-resistant prostate cancer that is not cytotoxic or based on hormone-related therapy. Provenge was launched in the US in 2010, and despite ...

For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...

In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration ...

Its prostate cancer immunotherapy vaccine Provenge initially promised great ... A further blow came when the UK health watchdog NICE rejected the drug in draft guidance in October, citing the ...

Unfortunately, between the immunological vision and the clinical validation lay a drug developers' nightmare. Provenge stuttered and stumbled through the regulatory pipe. Yes, it was relatively ...